Indole-3-carbinol and 3′,3′-diindolylmethane modulate androgen's effect on C-C chemokine ligand 2 and monocyte attraction to prostate cancer cells

Cancer Prevention Research

Volumn 6, Issue 6, 2013, Pages 519-529

  Kim, Eun Kyung ^a,b,c,e   Kim, Young S ^a   Milner, John A ^a,d   Wang, Thomas T Y ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c AGRICULTURAL RESEARCH SERVICE   (United States)

^d BELTSVILLE HUMAN NUTRITION RESEARCH CENTER   (United States)

^e Konkuk University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

3 INDOLEMETHANOL; 3,3' DIINDOLYLMETHANE; ANDROGEN RECEPTOR; ANDROSTANOLONE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1;

ARTICLE; CANCER CELL; CARCINOGENESIS; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE RELEASE; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; MONOCYTE; MONOCYTE MIGRATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN INDUCTION;

ANDROGENS; ANTICARCINOGENIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CCL2; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; MALE; MONOCYTES; NUCLEAR PROTEINS; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TWIST TRANSCRIPTION FACTOR;

EID: 84878889699     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-12-0419     Document Type: Article

References (49)

1. Zhu ML, Kyprianou N. Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells. FASEB J 2010;24:769-77.
2. De Marzo AM, Nelson WG, Meeker AK, Coffey DS. Stem cell features of benign and malignant prostate epithelial cells. J Urol 1998;160:2381-92. (Pubitemid 29483047)
3. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154-64. (Pubitemid 40096612)
4. Makhsida N, Shah J, Yan G, Fisch H, Shabsigh R. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol 2005;174:827-34. (Pubitemid 41140604)
5. Quigley CA, De Bellis A, Marschke KB, el-Awady MK, Wilson EM, French FS. Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev 1995;16:271-321.
6. Kuper H, Adami HO, Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med 2000;248:171-83. (Pubitemid 33702479)
7. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256-69. (Pubitemid 46486616)
8. MacLennan GT, Eisenberg R, Fleshman RL, Taylor JM, Fu P, Resnick MI, et al. The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study. J Urol 2006;176:1012-6. (Pubitemid 44142579)
9. Mahmud S, Franco E, Aprikian A. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer 2004;90:93-9. (Pubitemid 38174945)
10. Dennis LK, Lynch CF, Torner JC. Epidemiologic association between prostatitis and prostate cancer. Urology 2002;60:78-83. (Pubitemid 34722951)
11. Putzi MJ, De Marzo AM. Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology 2000;56:828-32.
12. Andreas B, David E, Nicolas K, Eva L, Marc SS, Johannes AS. Persistent in flammation leads to proliferative neoplasia and loss of smooth muscle cells in a prostate tumor model. Neoplasia 2011;13:692-703.
13. Tong S, Gwo-Shu ML, William KO, Matthew LF, Mark P, Kenneth JP, et al. Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort. Clin Cancer Res 2011;17:1546-52.
14. Jian Z, Yi L, Kenneth JP. Multiple roles of chemokine (C-C Motif) ligand 2 in promoting prostate cancer growth. J Natl Cancer Inst 2010;102:522-8.
15. Jian Z, Lalit P, Kenneth JP. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev 2010;21:41-8.
16. Loberg RD, Day LL, Harwood J, Chi Y, Lauren NJ, Ryan G, et al. CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia 2006;8:578-86. (Pubitemid 44061313)
17. Lu Y, Cai Z, Galson DL, Galson DL, Xiao G, Liu Y, et al. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate 2006;66:1311-8. (Pubitemid 44384308)
18. van Golen KL, Ying C, Sequeira L, Dubyk CW, Reisenberger T, Chinnaiyan AM, et al. CCL2 induces prostate cancer transendothelial cell migration via activation of the small GTPase Rac. J Cell Biochem 2008;104:1587-97.
19. Yanjia H, Xinchun J, Jieying P, Xiaowen J, Ning L, Shanghui Z. Gene expression profiling of oral submucous fibrosis using oligonucleotide microarray. Oncol Rep 2008;20:287-94.
20. Bruckheimer EM, Kyprianou N. Dihydrotestosterone enhances transforming growth factor-β-induced apoptosis in hormone-sensitive prostate cancer cells. Endocrinology 2001;142:2419-26. (Pubitemid 32473098)
21. Rosivatz E, Becker I, Specht K, Fricke E, Luber B, Busch R, et al. Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol 2002;161:1881-91. (Pubitemid 35265545)
22. Watanabe O, Imamura H, Shimizu T, Kinoshita J, Okabe T, Hirano A, et al. Expression of twist and wnt in human breast cancer. Anticancer Res 2004;24:3851-6. (Pubitemid 40468675)
23. Kwok WK, Ling MT, Lee TW, Lau TC, Zhou C, Zhang X, et al. Upregulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res 2005;65:5153-62. (Pubitemid 40827324)
24. Martin TA, Goyal A, Watkins G, Jiang WG. Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann Surg Oncol 2005;12:488-96. (Pubitemid 40884264)
25. Amanda TP, Jurga L, Niklas M, Erik N, Anne B, Ingrid D, et al. Apossible inflammatory role of TWIST1 in human white adipocytes. Diabetes 2010;59:564-71.
26. Niesner U, Albrecht I, Janke M, Doebis C, Loddenkemper C, Lexberg MH, et al. Autoregulation of Th1-mediated inflammation by twist1. J Exp Med 2008;205:1889-901.
27. SharifMN, Sosic D, Rothlin CV, Kelly E, Lemke G, Olson EN, et al. Twist mediates suppression of inflammation by type I IFNs and Axl. J Exp Med 2006;203:1891-901. (Pubitemid 44188464)
28. Pettersson AT, Mejhert N, Jernås M, Carlsson LM, Dahlman I, Laurencikiene J, et al. Twist1 in human white adipose tissue and obesity. J Clin Endocrinol Metab 2011;96:133-41.
29. Verhoeven DT, Goldbohm RA, van Poppel G, Verhagen H, van den Brandt PA. Epidemiological studies on brassica vegetables and cancer risk. Cancer Epidemiol Biomarkers Prev 1996;5:733-48. (Pubitemid 26304649)
30. Hong C, Kim HA, Firestone GL, Bjeldanes LF. 3,3′-Diindolylmethane (DIM) induces a G(1) cell cycle arrest in human breast cancer cells that is accompanied by Sp1-mediated activation of p21(WAF1/CIP1) expression. Carcinogenesis 2002;23:1297-305.
31. Chen I, McDougal A, Wang F, Safe S. Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindolylmethane. Carcinogenesis 1998;19:1631-9. (Pubitemid 28441867)
32. Daly C, Rollins BJ. Monocyte chemoattractant protein-1 (CCL2) in inflammatory disease and adaptive immunity: Therapeutic opportunities and controversies. Microcirculation 2003;10:247-57. (Pubitemid 39004252)
33. Wang TT, Schoene NW, Milner JA, Kim YS. Broccoli-derived phytochemicals indole-3-carbinol and 3,3′-diindolylmethane exerts concentration-dependent pleiotropic effects on prostate cancer cells: comparison with other cancer preventive phytochemicals. Mol Carcinog 2012;51:244-56.
34. Rogan EG. The natural chemopreventive compound Indole-3-carbinol: state of the science. In Vivo 2006;20:221-8.
35. Sarkar FH, Yiwei L, Zhiwei W, Dejuan K. The role of nutraceuticals in the regulation of Wnt and Hedgehog signaling in cancer. Cancer Metastasis Rev 2010;29:383-94.
36. Kim YH, Kwon HS, Kim DH, Shin EK, Kang YH, Park JH, et al. 3,3′-diindolylmethane attenuates colonic inflammation and tumorigenesis in mice. Inflamm Bowel Dis 2009;15:1164-73.
37. Oppenheim JJ, Zachariae COC, Mukaida N, Matsushima K. Properties of the novel proinflammatory supergene "intercrine" cytokine family. Annu Rev Immunol 1990;9:617-48.
38. Matsushima K, Baldwin ET, Mukaida N. Interleukin-8 and MCAF: Novel leukocyte recruitment and activating cytokines. Chem Immunol 1992;51:236-65.
39. Tosato G, Jones KD. Monocytes Interleukin-1 induces interleukin-6 production in peripheral blood. Blood 1990;75:1305-10. (Pubitemid 20107298)
40. Schetter AJ, Heegaard NHH, Harris CC. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 2010;31:37-49.
41. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010;29:4741-51.
42. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat Med 2009;15:1010-2.
43. Klarmann GJ, Hurt EM, Mathews LA, Zhang X, Duhagon MA, Mistree T, et al. Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis 2009;26:433-46.
44. Yuen HF, Kwok WK, Chan KK, Chua CW, Chan YP, Chu YY, et al. TWIST modulates prostate cancer cell-mediated bone cell activity and is upregulated by osteogenic induction. Carcinogenesis 2008;29:1509-18.
45. Olson EN, Klein WH. bHLH factors in muscle development: dead lines and commitments, what to leave in and what to leave out. Genes Dev 1994;8:1-8. (Pubitemid 24032848)
46. Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L, et al. Twist is a potential oncogene that inhibits apoptosis. Genes Dev 1999;13:2207-17. (Pubitemid 29426726)
47. Yuen HF, Chua CW, Chan YP, Wong YC, Wang X, Chan KW. Significance of TWIST and E-cadherin expression in the metastatic progression of prostatic cancer. Histopathology 2007;50:648-58. (Pubitemid 46495834)
48. Matsushima K, Larsen CG, Dubois GC, Oppenheim JJ. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med 1989;169:1485-90. (Pubitemid 19104979)
49. Brzezińska-Bøaszczyk E, Pietrzak A, Misiak-Tøoczek AH. Tumor necrosis factor (TNF) is a potent rat mast cell chemoattractant. J Interferon Cytokine Res 2007;27:911-9. (Pubitemid 350223111)